此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Prone to Supine Breast MRI Trial

2021年8月26日 更新者:Timothy B. Rooney、Dartmouth-Hitchcock Medical Center
The purpose of this study is to determine whether a supine MRI obtained immediately after a standard diagnostic prone MRI exam, without a second injection of gadolinium (Gd) contrast material, would be of sufficient quality to allow the Radiologist to define the tumor edges ("segment" the tumor) so that a 3-D image of the tumor can be generated to form a BCL.

研究概览

地位

完全的

条件

详细说明

The purpose of this study is to find out whether additional MRI images taken with patients in a different position after completing a standard MRI are of sufficient quality to allow a radiologist to identify the edges of the tumor.

These additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.The information gathered in this study will make it more feasible to use a new device called the "breast cancer locator" to help surgeons more accurately remove breast cancers.

研究类型

介入性

注册 (实际的)

72

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New Hampshire
      • Lebanon、New Hampshire、美国、03756
        • Dartmouth Hitchcock Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Age > 18 years.
  • Female gender.
  • Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ
  • Tumor size at least 1 cm in diameter as visualized on mammogram or US.
  • A diagnostic breast MRI is considered to be clinically indicated.
  • Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.

Exclusion Criteria:

  • Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
  • Severe claustrophobia.
  • Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (eGFR < 30 ml/min/1.73m2).
  • History of median sternotomy.
  • Pregnancy. Patient attestation that they are not pregnant will be acceptable.
  • Patients who have received neoadjuvant chemotherapy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Prone to Supine MRI
The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Successful Segmentation of Supine MRI Images
大体时间:30 minutes
Determine what number of cases that can be successfully segmented both from using post-contrast prone MRI images and also from using post contrast supine MRI images.
30 minutes

次要结果测量

结果测量
措施说明
大体时间
Enhancement Quantification, as Measured by Signal Intensity - Segmented Tumor
大体时间:30 minutes
Compare the signal intensity with that obtained at tumor location on the prone and supine imaging. The amount of enhancement at the tumor site = segmented tumor.
30 minutes
Enhancement Quantification, as Measured by Signal Intensity - Tumor Boundary
大体时间:30 minutes
Compare the signal intensity with that obtained in benign tissue surrounding the tumor on the prone and supine imaging.
30 minutes
Enhancement Quantification- Tumor-to-Background Ratio
大体时间:30 minutes
Mean MRI signal of the segmented tumor divided by the mean MRI signal of the surrounding tissue which has an equal volume to the tumor. The difference between tumor and benign breast tissue is the tumor-to-background ratio
30 minutes
Time to Position and Obtain Supine Images
大体时间:30 Minutes
Calculate the additional time needed to obtain supine MRI images. After the completion of Prone imaging, the patient was removed from the MRI, turned over to the supine position, new coils placed, and returned to the MRI for additional imaging. The aggregate time to accomplish these tasks are noted in minutes.
30 Minutes
Overall Comfort for Prone and Supine Positions
大体时间:Within 15 minutes of the scan
Quantify the perceived comfort level of the prone and supine MRI as reported by participants. A single question using a Likert scale was was used. The scale range was 0 to 5, where 0 = no pain, completely comfortable and 5 = considerable discomfort.
Within 15 minutes of the scan

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Timothy B Rooney, MD、Dartmouth-Hitchcock Medical Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年7月12日

初级完成 (实际的)

2020年7月31日

研究完成 (实际的)

2020年7月31日

研究注册日期

首次提交

2018年6月19日

首先提交符合 QC 标准的

2018年6月19日

首次发布 (实际的)

2018年6月29日

研究记录更新

最后更新发布 (实际的)

2021年8月30日

上次提交的符合 QC 标准的更新

2021年8月26日

最后验证

2021年8月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • D17168

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅